Yıl: 2023 Cilt: 30 Sayı: 8 Sayfa Aralığı: 868 - 872 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.04.100 İndeks Tarihi: 01-11-2023

Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions

Öz:
Aim: Respiratory syncytial virus is one of the most important causes of lower respiratory tract infections, with high mortality and morbidity in infants and children. It can cause airway inflammation, mucosal edema, and small airway collapse. Materials and Methods: We evaluated the clinical and demographic characteristics of newborns aged 0-30 days who were hospitalized in Yüzüncü Yıl University Neonatal Intensive Care Unit due to lower respiratory tract infections and whose respiratory syncytial virus test was positive between 15/December/2022 and 15/February/2023. Results: Between the specified dates, 29 patients diagnosed with lower respiratory tract infections were admitted to our neonatal unit. Of the oral/nasopharyngeal swab samples sent from all of these patients, one was positive for SARS-CoV-2, one for adenovirus, one for influenza A/B, and 18 (62%) respiratory syncytial virus. The weeks of the birth of the patients who were found to be positive for respiratory syncytial virus A/B were 36.72±1.48. The number of days they spent in the hospital was 6.72±1.6, 2(11.1%) patients required intubation, and 7(38.8%) patients required noninvasive respiratory support. One patient presented with convulsions at home, and cough and fever symptoms appeared on the second day of hospitalization. All patients recovered with oxygen support, hydration, and supportive treatment and were discharged. Conclusion: The most common cause in neonates was found to be a respiratory syncytial virus. Early diagnosis and treatment are important in patients with suspected lower tract viral infections. Unnecessary antibiotic use and the spread of the disease should be prevented by increasing access to viral tests.
Anahtar Kelime: Respiratory syncytial virus Neonate Lower respiratory tract infections COVID-19 pandemic

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Respiratory Syncytial Virus Infection (RSV) For Healthcare Providers(internet).USA: Centers for Disease Control and Prevention (accessed 1/3/2023) available form:https://www.cdc.gov/rsv/clinical/index.html#print.
  • 2. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2. PMID: 34783356; PMCID: PMC8594174.
  • 3. Baraldi E, Checcucci Lisi G, Costantino C, Heinrichs JH, Manzoni P, Riccò M. et al. RSV disease in infants and young children: Can we see a brighter future? Hum Vaccin Immunother. 2022 Nov 30;18(4):2079322. doi: 10.1080/21645515.2022.2079322. Epub 2022 Jun 20. PMID: 35724340; PMCID: PMC9721445.
  • 4. Respiratory Syncytial Virus Infection (RSV) in Infants and Young Children (internet).USA: Centers for Disease Control and Prevention (accessed 1/3/2023) available form:https://www.cdc.gov/rsv/high-risk/infants-youngchildren.html.
  • 5. Azzari C, Baraldi E, Bonanni P, Bozzola E, Coscia A, Lanari M. et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital J Pediatr. 2021 Oct 2;47(1):198. doi: 10.1186/s13052-021-01148-8. PMID: 34600591; PMCID: PMC8487331.
  • 6. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A. et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014 Oct 24;40:65. doi: 10.1186/1824-7288-40-65.
  • 7. Vakrilova L, Nikolova SH, Slavov S, Radulova P, Slancheva B. An outbreak of RSV infections in a neonatology clinic during the RSV-season. BMC Pediatr. 2021 Dec 11;21(1):567. doi: 10.1186/s12887-021-03053-9. PMID: 34895173; PMCID: PMC8665584.
  • 8. Bonati PCR, Furtado MCC, Mello DF, Wolkers PCB, Faria GO, Ferreira DMLM. Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies. Rev Bras Enferm. 2022;75(6):e20210362.
  • 9. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL. et al. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013 May 9;368(19):1791-9. doi: 10.1056/NEJMoa1211917. Erratum in: N Engl J Med. 2016 Jun 16;374(24):2406. PMID: 23656644.
  • 10. Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. Eur J Pediatr. 2018 Jun;177(6):913-920. doi: 10.1007/s00431-018-3138-6. Epub 2018 Apr 13. PMID: 29654399; PMCID: PMC5958152.
  • 11. Coutts J, Fullarton J, Morris C, Grubb E, Buchan S, Rodgers-Gray B, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55(5):1104–10. https://doi.org/1 0.1002/ppul.24676.
  • 12. Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:556-569. https://doi.org/10.1002/ppul.23570.
  • 13. Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A. et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020 Feb;33:35-44.
  • 14. Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. [Updated 2022 Nov 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459215/.
  • 15. Krause, Christine I. DNP, APRN, FNP-BC, PNP-BC. The ABCs of RSV. The Nurse Practitioner 43(9):p 20-26, September 2018. | DOI:10.1097/01.NPR.0000544277.74514.55.
  • 16. Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. Journal of global health 2015;5:020416.
  • 17. Hall CB, Simőes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39-57.
  • 18. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J. et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS study group. Pediatr Infect Dis J 2000;19:592–597.
  • 19. Law BJ, Langley JM, Allen U, Paes B, Lee DS et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–814.
  • 20. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R et al.Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010;182(10):1305–1314.
  • 21. Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006;193:54– 8.
  • 22. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–598.
  • 23. Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. J Pediatr (Rio J). 2017 Nov-Dec;93 Suppl 1:75-83. doi: 10.1016/j.jped.2017.07.003. Epub 2017 Aug 30. PMID: 28859915.
APA AYCAN N, Yürektürk E, Ateş A, Toplar E, Karaman S, Tuncer O (2023). Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. , 868 - 872. 10.5455/annalsmedres.2023.04.100
Chicago AYCAN Nur,Yürektürk Eyyüp,Ateş Ali,Toplar Emel Nadya,Karaman Serap,Tuncer Oğuz Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. (2023): 868 - 872. 10.5455/annalsmedres.2023.04.100
MLA AYCAN Nur,Yürektürk Eyyüp,Ateş Ali,Toplar Emel Nadya,Karaman Serap,Tuncer Oğuz Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. , 2023, ss.868 - 872. 10.5455/annalsmedres.2023.04.100
AMA AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. . 2023; 868 - 872. 10.5455/annalsmedres.2023.04.100
Vancouver AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. . 2023; 868 - 872. 10.5455/annalsmedres.2023.04.100
IEEE AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O "Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions." , ss.868 - 872, 2023. 10.5455/annalsmedres.2023.04.100
ISNAD AYCAN, Nur vd. "Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions". (2023), 868-872. https://doi.org/10.5455/annalsmedres.2023.04.100
APA AYCAN N, Yürektürk E, Ateş A, Toplar E, Karaman S, Tuncer O (2023). Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. Annals of Medical Research, 30(8), 868 - 872. 10.5455/annalsmedres.2023.04.100
Chicago AYCAN Nur,Yürektürk Eyyüp,Ateş Ali,Toplar Emel Nadya,Karaman Serap,Tuncer Oğuz Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. Annals of Medical Research 30, no.8 (2023): 868 - 872. 10.5455/annalsmedres.2023.04.100
MLA AYCAN Nur,Yürektürk Eyyüp,Ateş Ali,Toplar Emel Nadya,Karaman Serap,Tuncer Oğuz Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. Annals of Medical Research, vol.30, no.8, 2023, ss.868 - 872. 10.5455/annalsmedres.2023.04.100
AMA AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. Annals of Medical Research. 2023; 30(8): 868 - 872. 10.5455/annalsmedres.2023.04.100
Vancouver AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions. Annals of Medical Research. 2023; 30(8): 868 - 872. 10.5455/annalsmedres.2023.04.100
IEEE AYCAN N,Yürektürk E,Ateş A,Toplar E,Karaman S,Tuncer O "Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions." Annals of Medical Research, 30, ss.868 - 872, 2023. 10.5455/annalsmedres.2023.04.100
ISNAD AYCAN, Nur vd. "Respiratory syncytial virus dominance in pneumonia cases after removal of pandemic restrictions". Annals of Medical Research 30/8 (2023), 868-872. https://doi.org/10.5455/annalsmedres.2023.04.100